Format
Sort by
Items per page

Send to

Choose Destination

Best matches for ibogaine:

How toxic is ibogaine? Litjens RP et al. Clin Toxicol (Phila). (2016)

Ibogaine in the treatment of substance dependence. Brown TK et al. Curr Drug Abuse Rev. (2013)

[Ibogaine - structure, influence on human body, clinical relevance]. Zdrojewicz Z et al. Pol Merkur Lekarski. (2016)

Search results

Items: 1 to 20 of 467

1.

On Addiction, Complexity, and Freedom: Toward a Liberation-Focused Addiction Treatment.

Kellogg S.

J Psychoactive Drugs. 2019 Jan 17:1-8. doi: 10.1080/02791072.2018.1564157. [Epub ahead of print]

PMID:
30653394
2.

Metabolite Profiling of Antiaddictive Alkaloids from Four Mexican Tabernaemontana Species and the Entheogenic African Shrub Tabernanthe iboga (Apocynaceae).

Krengel F, Chevalier Q, Dickinson J, Santoyo JH, Reyes-Chilpa R.

Chem Biodivers. 2019 Jan 7. doi: 10.1002/cbdv.201800506. [Epub ahead of print]

PMID:
30618175
3.

Phytochemical characterization of Tabernanthe iboga root bark and its effects on dysfunctional metabolism and cognitive performance in high-fat-fed C57BL/6J mice.

Bading-Taika B, Akinyeke T, Magana AA, Choi J, Ouanesisouk M, Torres ERS, Lione LA, Maier CS, Bobe G, Raber J, Miranda CL, Stevens JF.

J Food Bioact. 2018 Sep;3:111-123. doi: 10.31665/JFB.2018.3154. Epub 2018 Sep 30.

4.

Ibogaine as a treatment for substance misuse: Potential benefits and practical dangers.

Corkery JM.

Prog Brain Res. 2018;242:217-257. doi: 10.1016/bs.pbr.2018.08.005. Epub 2018 Oct 12.

PMID:
30471681
5.

A case report SPECT study and theoretical rationale for the sequential administration of ibogaine and 5-MeO-DMT in the treatment of alcohol use disorder.

Barsuglia JP, Polanco M, Palmer R, Malcolm BJ, Kelmendi B, Calvey T.

Prog Brain Res. 2018;242:121-158. doi: 10.1016/bs.pbr.2018.08.002. Epub 2018 Oct 25.

PMID:
30471678
6.

Hallucinogen Persisting Perception Disorder After Ibogaine Treatment for Opioid Dependence.

Knuijver T, Belgers M, Markus W, Verkes RJ, van Oosteren T, Schellekens A.

J Clin Psychopharmacol. 2018 Dec;38(6):646-648. doi: 10.1097/JCP.0000000000000966. No abstract available.

PMID:
30300292
7.

Subjective effectiveness of ibogaine treatment for problematic opioid consumption: Short- and long-term outcomes and current psychological functioning.

Davis AK, Barsuglia JP, Windham-Herman AM, Lynch M, Polanco M.

J Psychedelic Stud. 2017 Nov;1(2):65-73. doi: 10.1556/2054.01.2017.009. Epub 2017 Oct 17.

8.

DARK Classics in Chemical Neuroscience: Ibogaine.

Wasko MJ, Witt-Enderby PA, Surratt CK.

ACS Chem Neurosci. 2018 Oct 17;9(10):2475-2483. doi: 10.1021/acschemneuro.8b00294. Epub 2018 Oct 9.

PMID:
30216039
9.

Cardiac arrest after ibogaine intoxication.

Steinberg C, Deyell MW.

J Arrhythm. 2018 Jun 12;34(4):455-457. doi: 10.1002/joa3.12061. eCollection 2018 Aug.

10.

Wastewater-based epidemiology in low Human Development Index states: bias in consumption monitoring of illicit drugs.

Devault DA, Maguet H, Merle S, Péné-Annette A, Lévi Y.

Environ Sci Pollut Res Int. 2018 Oct;25(28):27819-27838. doi: 10.1007/s11356-018-2864-7. Epub 2018 Aug 14. Review.

PMID:
30109683
11.

Cytochrome P450 and O-methyltransferase catalyze the final steps in the biosynthesis of the anti-addictive alkaloid ibogaine from Tabernanthe iboga.

Farrow SC, Kamileen MO, Meades J, Ameyaw B, Xiao Y, O'Connor SE.

J Biol Chem. 2018 Sep 7;293(36):13821-13833. doi: 10.1074/jbc.RA118.004060. Epub 2018 Jul 20.

12.

Psychedelic-Assisted Psychotherapy: A Paradigm Shift in Psychiatric Research and Development.

Schenberg EE.

Front Pharmacol. 2018 Jul 5;9:733. doi: 10.3389/fphar.2018.00733. eCollection 2018.

13.

A Mixed-Method Analysis of Persisting Effects Associated with Positive Outcomes Following Ibogaine Detoxification.

Davis AK, Renn E, Windham-Herman AM, Polanco M, Barsuglia JP.

J Psychoactive Drugs. 2018 Sep-Oct;50(4):287-297. doi: 10.1080/02791072.2018.1487607. Epub 2018 Jul 18.

PMID:
30020025
14.

Nepenthe-Like Indole Alkaloids with Antimicrobial Activity from Ervatamia chinensis.

Yu HF, Qin XJ, Ding CF, Wei X, Yang J, Luo JR, Liu L, Khan A, Zhang LC, Xia CF, Luo XD.

Org Lett. 2018 Jul 6;20(13):4116-4120. doi: 10.1021/acs.orglett.8b01675. Epub 2018 Jun 21.

PMID:
29927253
15.

Ibogaine Detoxification Transitions Opioid and Cocaine Abusers Between Dependence and Abstinence: Clinical Observations and Treatment Outcomes.

Mash DC, Duque L, Page B, Allen-Ferdinand K.

Front Pharmacol. 2018 Jun 5;9:529. doi: 10.3389/fphar.2018.00529. eCollection 2018.

16.

Ibogaine Acute Administration in Rats Promotes Wakefulness, Long-Lasting REM Sleep Suppression, and a Distinctive Motor Profile.

González J, Prieto JP, Rodríguez P, Cavelli M, Benedetto L, Mondino A, Pazos M, Seoane G, Carrera I, Scorza C, Torterolo P.

Front Pharmacol. 2018 Apr 27;9:374. doi: 10.3389/fphar.2018.00374. eCollection 2018.

17.

Changes in Withdrawal and Craving Scores in Participants Undergoing Opioid Detoxification Utilizing Ibogaine.

Malcolm BJ, Polanco M, Barsuglia JP.

J Psychoactive Drugs. 2018 Jul-Aug;50(3):256-265. doi: 10.1080/02791072.2018.1447175. Epub 2018 Apr 2.

PMID:
29608409
18.

The Effects of Ibogaine on Uterine Smooth Muscle Contractions: Relation to the Activity of Antioxidant Enzymes.

Oreščanin-Dušić Z, Tatalović N, Vidonja-Uzelac T, Nestorov J, Nikolić-Kokić A, Mijušković A, Spasić M, Paškulin R, Bresjanac M, Blagojević D.

Oxid Med Cell Longev. 2018 Feb 11;2018:5969486. doi: 10.1155/2018/5969486. eCollection 2018.

19.

Breaking the cycle of opioid use disorder with Ibogaine.

C Mash D.

Am J Drug Alcohol Abuse. 2018;44(1):1-3. doi: 10.1080/00952990.2017.1357184. Epub 2017 Dec 7. No abstract available.

PMID:
29215917
20.

SLC6 Transporter Folding Diseases and Pharmacochaperoning.

Freissmuth M, Stockner T, Sucic S.

Handb Exp Pharmacol. 2018;245:249-270. doi: 10.1007/164_2017_71. Review.

PMID:
29086036

Supplemental Content

Loading ...
Support Center